1-17 of 17
Ana Lluch
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P5-02-25: Deciphering the transcriptomic landscape of early HR+/HER2- breast cancer in very young women

Free
Marta Tapia, Iris Garrido-Cano, Juan Carbonell, Carlos Peña, Sandra Torres-Ruiz, Anna Ágreda-Roca, Cristina Tébar, Octavio Burgués, Cristina Hernando, Ana Lluch, Begoña Bermejo, María Teresa Martínez, Juan Miguel Cejalvo
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P5-02-25.
https://doi.org/10.1158/1557-3265.SABCS24-P5-02-25
Published: 13 June 2025
View articletitled, Abstract P5-02-25: Deciphering the transcriptomic landscape of early HR+/HER2- breast cancer in very young women
Journal Articles

Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

Open Access
Karama Asleh, Ana Lluch, Angela Goytain, Carlos Barrios, Xue Q. Wang, Laura Torrecillas, Dongxia Gao, Manuel Ruiz-Borrego, Samuel Leung, José Bines, Ángel Guerrero-Zotano, Jose Ángel García-Sáenz, Juan Miguel Cejalvo, Jesus Herranz, Roberto Torres, Juan de la Haba-Rodriguez, Francisco Ayala, Henry Gómez, Federico Rojo, Torsten O. Nielsen, Miguel Martin
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (2): 389–400.
https://doi.org/10.1158/1078-0432.CCR-22-2191
Published: 17 January 2023
View articletitled, Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
Open the PDF for Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine in another window
Includes: Supplementary data
Journal Articles

Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer

Available to Purchase
Cristina Guardia, Giampaolo Bianchini, Oriol Arpí-LLucià, Silvia Menendez, David Casadevall, Barbara Galbardi, Matteo Dugo, Sonia Servitja, Juan Carlos Montero, Luis Soria-Jiménez, MohammadA Sabbaghi, Raul Peña, Juan Madoz-Gúrpide, Belen Lloveras, Ana Lluch, Pilar Eroles, Joaquin Arribas, Atanasio Pandiella, Luca Gianni, Federico Rojo, Ana Rovira, Joan Albanell
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (18): 5096–5108.
https://doi.org/10.1158/1078-0432.CCR-20-2915
Published: 15 September 2021
View articletitled, Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer
Open the PDF for Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation

Available to Purchase
Patricia Fernández-Nogueira, Mario Mancino, Gemma Fuster, Anna López-Plana, Patricia Jauregui, Vanesa Almendro, Estel Enreig, Silvia Menéndez, Federico Rojo, Aleix Noguera-Castells, Anke Bill, L. Alex Gaither, Laia Serrano, Leire Recalde-Percaz, Núria Moragas, Raul Alonso, Elisabet Ametller, Ana Rovira, Ana Lluch, Joan Albanell, Pere Gascon, Paloma Bragado
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (6): 1432–1448.
https://doi.org/10.1158/1078-0432.CCR-19-0353
Published: 13 March 2020
View articletitled, Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
Open the PDF for Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation in another window
Includes: Supplementary data
Journal Articles

NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival

Free
Aura Muntasell, Federico Rojo, Sonia Servitja, Carlota Rubio-Perez, Mariona Cabo, David Tamborero, Marcel Costa-García, María Martínez-Garcia, Sílvia Menéndez, Ivonne Vazquez, Ana Lluch, Abel Gonzalez-Perez, Ana Rovira, Miguel López-Botet, Joan Albanell
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (5): 1535–1545.
https://doi.org/10.1158/1078-0432.CCR-18-2365
Published: 01 March 2019
View articletitled, NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival
Open the PDF for NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival in another window
Includes: Supplementary data
Journal Articles

Correction: ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

Free
Angel L. Guerrero-Zotano, Thomas P. Stricker, Luigi Formisano, Katherine E. Hutchinson, Daniel G. Stover, Kyung-Min Lee, Luis J. Schwarz, Jennifer M. Giltnane, Monica V. Estrada, Valerie M. Jansen, Alberto Servetto, Joaquín Gavilá, J. Alejandro Perez-Fidalgo, Ana Lluch, Antonio Llombart-Cussac, Mohamed Amine Bayar, Stefan Michiels, Fabrice André, Mónica Arnedos, Vicente Guillem, Amparo Ruiz-Simon, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1431.
https://doi.org/10.1158/1078-0432.CCR-18-4270
Published: 15 February 2019
View articletitled, Correction: ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
Open the PDF for Correction: ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors in another window
Journal Articles

ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

Free
Angel L. Guerrero-Zotano, Thomas P. Stricker, Luigi Formisano, Katherine E. Hutchinson, Daniel G. Stover, Kyung-Min Lee, Luis J. Schwarz, Jennifer M. Giltnane, Monica V. Estrada, Valerie M. Jansen, Alberto Servetto, Joaquín Gavilá, J. Alejandro Perez-Fidalgo, Ana Lluch, Antonio Llombart-Cussac, Mohamed Amine Bayar, Stefan Michiels, Fabrice André, Mónica Arnedos, Vicente Guillem, Amparo Ruiz-Simon, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (11): 2517–2529.
https://doi.org/10.1158/1078-0432.CCR-17-2904
Published: 31 May 2018
View articletitled, ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
Open the PDF for ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors in another window
Includes: Supplementary data
Journal Articles

Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer

Free
MohammadA Sabbaghi, Gabriel Gil-Gómez, Cristina Guardia, Sonia Servitja, Oriol Arpí, Sara García-Alonso, Silvia Menendez, Montserrat Arumi-Uria, Laia Serrano, Marta Salido, Aura Muntasell, Maria Martínez-García, Sandra Zazo, Cristina Chamizo, Paula González-Alonso, Juan Madoz-Gúrpide, Pilar Eroles, Joaquin Arribas, Ignasi Tusquets, Ana Lluch, Atanasio Pandiella, Federico Rojo, Ana Rovira, Joan Albanell
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (22): 7006–7019.
https://doi.org/10.1158/1078-0432.CCR-17-0696
Published: 14 November 2017
View articletitled, Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer
Open the PDF for Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse

Free
Aleix Prat, Ana Lluch, Arran K. Turnbull, Anita K. Dunbier, Lourdes Calvo, Joan Albanell, Juan de la Haba-Rodríguez, Angels Arcusa, José Ignacio Chacón, Pedro Sánchez-Rovira, Arrate Plazaola, Montserrat Muñoz, Laia Paré, Joel S. Parker, Nuria Ribelles, Begoña Jimenez, Abdul Aziz Bin Aiderus, Rosalía Caballero, Barbara Adamo, Mitch Dowsett, Eva Carrasco, Miguel Martín, J. Michael Dixon, Charles M. Perou, Emilio Alba
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (12): 3035–3044.
https://doi.org/10.1158/1078-0432.CCR-16-2092
Published: 14 June 2017
View articletitled, A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse
Open the PDF for A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse in another window
Includes: Supplementary data
Journal Articles

18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial

Free
Miguel Quintela-Fandino, Ana Lluch, Luis Manso, Isabel Calvo, Javier Cortes, José Angel García-Saenz, Miguel Gil-Gil, Noelia Martinez-Jánez, Antonio Gonzalez-Martin, Encarna Adrover, Raquel de Andres, Gemma Viñas, Antonio Llombart-Cussac, Emilio Alba, Juan Guerra, Begoña Bermejo, Esther Zamora, Fernando Moreno-Anton, Sonia Pernas Simon, Alfredo Carrato, Antonio Lopez-Alonso, María José Escudero, Ruth Campo, Eva Carrasco, José Palacios, Francisca Mulero, Ramon Colomer
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (6): 1432–1441.
https://doi.org/10.1158/1078-0432.CCR-16-0738
Published: 14 March 2017
View articletitled, 18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial
Open the PDF for 18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial in another window
Includes: Supplementary data
Journal Articles

Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer

Free
Adel Tabchy, Vicente Valero, Tatiana Vidaurre, Ana Lluch, Henry Gomez, Miguel Martin, Yuan Qi, Luis Javier Barajas-Figueroa, Eduardo Souchon, Charles Coutant, Franco D. Doimi, Nuhad K. Ibrahim, Yun Gong, Gabriel N. Hortobagyi, Kenneth R. Hess, W. Fraser Symmans, Lajos Pusztai
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (21): 5351–5361.
https://doi.org/10.1158/1078-0432.CCR-10-1265
Published: 31 October 2010
View articletitled, Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer
Open the PDF for Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer

Free
Roshan Agarwal, Ana-Maria Gonzalez-Angulo, Simen Myhre, Mark Carey, Ju-Seog Lee, Jens Overgaard, Jan Alsner, Katherine Stemke-Hale, Ana Lluch, Richard M. Neve, Wen Lin Kuo, Therese Sorlie, Aysegul Sahin, Vicente Valero, Khandan Keyomarsi, Joe W. Gray, Anne-Lise Borresen-Dale, Gordon B. Mills, Bryan T. Hennessy
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (11): 3654–3662.
https://doi.org/10.1158/1078-0432.CCR-08-3293
Published: 01 June 2009
View articletitled, Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer
Open the PDF for Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study

Free
Javier Cortes, Serena Di Cosimo, Miguel A. Climent, Hernán Cortés-Funes, Ana Lluch, Pere Gascón, José I. Mayordomo, Miguel Gil, Manuel Benavides, Lluís Cirera, Belén Ojeda, César A. Rodríguez, José M. Trigo, Josep Vazquez, Pilar Regueiro, Juan F. Dorado, José Baselga, on behalf of the Spanish Breast Cancer Cooperative Group SOLTI
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (1): 307–314.
https://doi.org/10.1158/1078-0432.CCR-08-1113
Published: 31 December 2008
View articletitled, Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study
Open the PDF for Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study in another window
Journal Articles

p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer

Free
Rosana Sáez, Miguel A. Molina, Elizabeth E. Ramsey, Federico Rojo, Edward J. Keenan, Joan Albanell, Ana Lluch, Javier García-Conde, José Baselga, Gail M. Clinton
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (2): 424–431.
https://doi.org/10.1158/1078-0432.CCR-05-1807
Published: 20 January 2006
View articletitled, p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer
Open the PDF for p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer in another window
Journal Articles

Genomic Loss of 18p Predicts an Adverse Clinical Outcome in Patients with High-Risk Breast Cancer

Free
Joan Climent, Jose A. Martinez-Climent, David Blesa, Maria J. Garcia-Barchino, Rosana Saez, Dolors Sánchez-Izquierdo, Pilar Azagra, Ana Lluch, Javier Garcia-Conde
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (12): 3863–3869.
Published: 01 December 2002
View articletitled, Genomic Loss of 18p Predicts an Adverse Clinical Outcome in Patients with High-Risk Breast Cancer
Open the PDF for Genomic Loss of 18p Predicts an Adverse Clinical Outcome in Patients with High-Risk Breast Cancer in another window
Journal Articles

NH2-terminal Truncated HER-2 Protein but not Full-Length Receptor Is Associated with Nodal Metastasis in Human Breast Cancer

Free
Miguel A. Molina, Rosana Sáez, Elizabeth E. Ramsey, María-José Garcia-Barchino, Federico Rojo, Adam J. Evans, Joan Albanell, Edward J. Keenan, Ana Lluch, Javier García-Conde, José Baselga, Gail M. Clinton
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (2): 347–353.
Published: 01 February 2002
View articletitled, NH2-terminal Truncated HER-2 Protein but not Full-Length Receptor Is Associated with Nodal Metastasis in Human Breast Cancer
Open the PDF for NH2-terminal Truncated HER-2 Protein but not Full-Length Receptor Is Associated with Nodal Metastasis in Human Breast Cancer in another window
Journal Articles

Circulating HER2 Extracellular Domain and Resistance to Chemotherapy in Advanced Breast Cancer

Free
Ramon Colomer, Sagrario Montero, Ana Lluch, Belén Ojeda, Agustí Barnadas, Antonio Casado, Bartomeu Massutí, Hernán Cortés-Funes, Belén Lloveras
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (6): 2356–2362.
Published: 01 June 2000
View articletitled, Circulating HER2 Extracellular Domain and Resistance to Chemotherapy in Advanced Breast Cancer
Open the PDF for Circulating HER2 Extracellular Domain and Resistance to Chemotherapy in Advanced Breast Cancer in another window